CDC.govMunich-based Innovative Molecules steps into the spotlight with a partnership with Italy’s Alfasigma. The deal brings fresh capital and a global licence for adibelivir, a next-generation antiviral targeting the ultra-rare, life-threatening Herpes Simplex Virus (HSV) encephalitis.
ADVERTISEMENT